No Data
The Covid Era Tech Promises To Reinvent Cancer Treatment
Merck to Post 3Q Charge of About 28c/Share on Curon Deal >MRK
Express News | Merck & Co Inc - Recording Pre-Tax Charge of $750 Million, or $0.28 per Share
Express News | Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, Cn201, From Curon Biopharmaceutical
Merck & Co., Inc. (MRK) Projects 21% Upside With $140 Price Target as Keytruda and New Vaccines Drive Growth
Stocks With the Highest Consensus of Expected ROE Growth, Goldman Sachs Says